RGNX vs TNYA
RGNX: A clinical-stage gene therapy developer leveraging its proprietary AAV platform to create potentially curative, one-time treatments for serious genetic diseases. TNYA: Tenaya Therapeutics is a clinical-stage precision medicine company developing curative, genetically-driven therapies to treat the root causes of heart disease.
Side-by-side fundamentals
| Metric | RGNX | TNYA | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $7.40 | $0.41 | |
| Market cap | $488M | $92M | |
| Net margin FY2025, SEC XBRL | -113.8% | n/a | |
| Operating margin FY2025, SEC XBRL | -94.6% | n/a | |
| ROE FY2025, SEC XBRL | -188.7% | -73.5% | TNYA higher |
| ROA FY2025, SEC XBRL | -42.8% | -61.7% | RGNX higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +104.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +14.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.89 | 1.79 | |
| 1-year return as of 2026-10-20 close | -41.5% | -79.2% | RGNX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.